Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 92 filers reported holding Y-MABS THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $28,097,000 | -0.7% | 1,948,469 | +4.2% | 0.01% | 0.0% |
| Q2 2022 | $28,299,000 | +24.7% | 1,870,379 | -2.1% | 0.01% | +50.0% |
| Q1 2022 | $22,698,000 | -67.2% | 1,910,578 | -55.3% | 0.00% | -63.6% |
| Q4 2021 | $69,239,000 | -43.3% | 4,271,382 | -0.2% | 0.01% | -47.6% |
| Q3 2021 | $122,097,000 | -18.8% | 4,278,097 | -3.8% | 0.02% | -16.0% |
| Q2 2021 | $150,363,000 | +64.6% | 4,448,610 | +47.3% | 0.02% | +56.2% |
| Q1 2021 | $91,338,000 | -24.4% | 3,020,458 | +23.8% | 0.02% | -27.3% |
| Q4 2020 | $120,794,000 | +18.5% | 2,439,809 | -8.1% | 0.02% | +4.8% |
| Q3 2020 | $101,927,000 | +1.4% | 2,655,052 | +14.1% | 0.02% | -4.5% |
| Q2 2020 | $100,566,000 | +40.4% | 2,327,926 | -15.2% | 0.02% | +15.8% |
| Q1 2020 | $71,626,000 | -6.7% | 2,744,305 | +11.7% | 0.02% | +18.8% |
| Q4 2019 | $76,769,000 | +617.5% | 2,456,626 | +498.3% | 0.02% | +700.0% |
| Q3 2019 | $10,700,000 | – | 410,615 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 191,176 | $2,271,000 | 2.63% |
| Sofinnova Investments, Inc. | 2,194,278 | $26,068,000 | 1.98% |
| MPM BioImpact LLC | 443,702 | $5,271,000 | 1.42% |
| Soleus Capital Management, L.P. | 238,982 | $2,839,000 | 0.37% |
| Lombard Odier Asset Management (Switzerland) SA | 221,774 | $2,635,000 | 0.21% |
| Artal Group S.A. | 400,000 | $4,752,000 | 0.20% |
| Polar Capital Holdings Plc | 2,877,671 | $34,187,000 | 0.15% |
| ASHFORD CAPITAL MANAGEMENT INC | 106,770 | $1,268,000 | 0.14% |
| Cormorant Asset Management, LP | 150,000 | $1,782,000 | 0.14% |
| Virtus ETF Advisers LLC | 23,646 | $281,000 | 0.13% |